Campbell David Alan, President and CEO of Janux Therapeutics Inc. ($JANX), made one open market sale of common shares in the last year, totaling $110,829. His most recent sale occurred on January 2, 2026. Among 11,678 insiders with sales, his amount ranks 9,415th, well below the average of $8.6 million over 6.4 transactions. He reported no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 2, 2026 | Janux Therapeutics, Inc. | $JANX | Campbell David Alan | President and CEO | S | Common Stock | 8072 | $13.73 | 284,982.0000 | 62,023,685 | 2.75% | 0.01% |
| Jan. 2, 2026 | Janux Therapeutics, Inc. | $JANX | Campbell David Alan | President and CEO | A | Stock option (right to buy) | 338100 | $0.00 | 338,100.0000 | 62,023,685 | 9999.99% | 0.55% |
| Jan. 2, 2026 | Janux Therapeutics, Inc. | $JANX | Campbell David Alan | President and CEO | A | Common Stock | 96600 | $0.00 | 381,582.0000 | 62,023,685 | 33.90% | 0.16% |
| Jan. 7, 2025 | Janux Therapeutics, Inc. | $JANX | Campbell David Alan | President and CEO | S | Common Stock | 5000 | $60.00 | 293,054.0000 | 53,751,480 | 1.68% | 0.01% |
| Jan. 2, 2025 | Janux Therapeutics, Inc. | $JANX | Campbell David Alan | President and CEO | A | Common Stock | 81000 | $0.00 | 298,054.0000 | 53,751,480 | 37.32% | 0.15% |
| Jan. 2, 2025 | Janux Therapeutics, Inc. | $JANX | Campbell David Alan | President and CEO | A | Stock option (right to buy) | 283500 | $0.00 | 283,500.0000 | 53,751,480 | 9999.99% | 0.53% |
| Dec. 24, 2024 | Janux Therapeutics, Inc. | $JANX | Campbell David Alan | President and CEO | S | Common Stock | 25000 | $56.19 | 217,054.0000 | 54,628,670 | 10.33% | 0.05% |
| Dec. 3, 2024 | Janux Therapeutics, Inc. | $JANX | Campbell David Alan | President and CEO | S | Common Stock | 15000 | $67.00 | 242,054.0000 | 54,628,670 | 5.84% | 0.03% |
| Nov. 25, 2024 | Janux Therapeutics, Inc. | $JANX | Campbell David Alan | President and CEO | S | Common Stock | 6719 | $52.04 | 257,054.0000 | 54,628,670 | 2.55% | 0.01% |
| Nov. 25, 2024 | Janux Therapeutics, Inc. | $JANX | Campbell David Alan | President and CEO | S | Common Stock | 18281 | $51.43 | 263,773.0000 | 54,628,670 | 6.48% | 0.03% |
| Oct. 28, 2024 | Janux Therapeutics, Inc. | $JANX | Campbell David Alan | President and CEO | S | Common Stock | 11103 | $53.94 | 282,054.0000 | 54,628,670 | 3.79% | 0.02% |
| Oct. 28, 2024 | Janux Therapeutics, Inc. | $JANX | Campbell David Alan | President and CEO | S | Common Stock | 13897 | $53.22 | 293,157.0000 | 54,628,670 | 4.53% | 0.03% |
| Sept. 27, 2024 | Janux Therapeutics, Inc. | $JANX | Campbell David Alan | President and CEO | S | Common Stock | 18957 | $46.09 | 313,097.0000 | 44,016,283 | 5.71% | 0.04% |
| Sept. 27, 2024 | Janux Therapeutics, Inc. | $JANX | Campbell David Alan | President and CEO | S | Common Stock | 5248 | $46.86 | 307,849.0000 | 44,016,283 | 1.68% | 0.01% |
| Sept. 27, 2024 | Janux Therapeutics, Inc. | $JANX | Campbell David Alan | President and CEO | S | Common Stock | 795 | $47.84 | 307,054.0000 | 44,016,283 | 0.26% | 0.00% |
| Jan. 2, 2024 | Janux Therapeutics, Inc. | $JANX | Campbell David Alan | President and CEO | A | Stock Option (right to buy) | 356500 | $0.00 | 356,500.0000 | 44,016,283 | 9999.99% | 0.81% |